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Abstract
Eosinophilia-myalgia syndrome was described in 1989 in patients who presented progressive and incapacitating myalgia and eosinophilia 
in blood, fluids and secretions. Most patients report previous L-tryptophan intake. Respiratory manifestations are found in up to 80% of 
the cases, occasionally as the only manifestation. Treatment includes drug discontinuation and administration of corticosteroids. Here, we 
describe the case of a 61-year-old female admitted with acute respiratory failure after using L-tryptophan, hydroxytryptophan and other 
drugs. The patient presented eosinophilia, together with elevated eosinophil counts in the bronchoalveolar lavage and pleural effusion. After 
discontinuation of the drugs previously used, corticosteroids were administered, resulting in clinical and radiological improvement within 
just a few days. 
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Introduction
Eosinophilia-myalgia syndrome (EMS) was described 
in 1989, appearing in an epidemic manner when several 
patients presented incapacitating myalgia and peripheral 
eosinophilia after L-tryptophan intake. This led to the 
removal of L-tryptophan from the market.(1) Since then, 
more than 5000 cases have occurred, the majority in female 
white patients with a mean age of 49 years.(1-4)
L-tryptophan is an amino acid found in lean meats, fish, 
milk, cheese, nuts, and legumes. It is a natural precursor 
of serotonin and has been used to raise the organic levels 
of serotonin, to improve cognitive activities, and to treat 
depression, as well as to regulate sleep, sexual appetite, 
sensitivity to pain, and body temperature.(5)
L-tryptophan intake has been implicated as causal 
agent of EMS.(1,6,7) Some patients might present respiratory 
complaints and radiological alterations, and occasionally, 
they present without the involvement of other organs.
Here, we report a case of acute respiratory failure, 
presumably related to L-tryptophan intake.
Case report
A 61-year-old woman presented with a one-week 
history of progressive dyspnea, dry cough, and fever. She 
reported no myalgia, exanthema, chest pain, purulent 
expectoration, hemoptysis, previous pulmonary diseases, 
or any other chronic diseases, and she described herself as 
a nonsmoker. She reported weight loss (8 kg) in the last 
months and depression, for which, three weeks before the 
respiratory condition, she began taking a ‘formula’ that 
included L-tryptophan (2 g/day), 5-hydroxytryptophan 
(400 mg/day), L-taurine, glutamine, inositol, pantothenic 
acid, cyanocobalamin, pyridoxine, L-phosphoserine, phos-
phothreonine, fluoxetine, carisoprodol, and omeprazole.
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bronchograms), peripheral consolidations, and 
areas of ground-glass attenuation in the right 
lung;
•	Chest	ultrasound:	left	pleural	effusion,	without	
septations, which extended from the base to 
the upper third of the left hemithorax;
•	Thoracocentesis:	 bright	 yellow	 fluid,	 with	
protein: 3.7 g/dL (pleural protein/serum = 0.6), 
LDH = 242 U/L (LDH pleural/serum = 0.72), 
glucose = 104 mg/dL, 1960 leukocytes/mm3 
(47.5% neutrophils, 25.5% lymphocytes, 
24.5% eosinophils, and 1% basophils) and 
3000 erythocytes/mm3.
•	Testing	 and	 culture	 for	 fungi	 and	 bacteria:	
negative;
•	Bronchoscopy:	 bronchoalveolar	 lavage	 (BAL)	
with 53,000 cells/mL, with negative results of 
testing and culture for fungi and mycobac-
teria, and positive culture for Staphylococcus 
aureus;
•	Cytology	(BAL):	purulent	active	chronic	inflam-
matory exudate with frequent eosinophils, 
siderophores, and multinucleated giant cells 
of foreign-body type; and
•	Transbronchial	 biopsy:	 focus	 of	 incipient	
non-necrotic granulomatous reaction, in 
the bronchovascular region, with negative 
cultures.
The patient was initially treated for severe 
community-acquired pneumonia, with antibiotic 
Upon physical examination, she presented 
regular overall health status and fever, without 
alterations in cardiac auscultation. She presented 
dyspnea and tachypnea (respiratory rate between 
28 and 40 breaths/min). Upon inspection and 
palpation of the chest, reduced and symmetric 
expansibility was observed. Pulmonary auscultation 
revealed bilateral coarse crackles and rhonchi, which 
were predominant in the left hemithorax.
Complementary tests showed the following:
•	Arterial	 blood	 gas	 analysis	 (room	 air):	
pH = 7.55; arterial oxygen tension = 53 mmHg; 
arterial carbon dioxide tension = 23 mmHg; 
 peripheral oxygen saturation (SpO2) = 91%;
•	Blood	workup:	17,180	leukocytes/mm3, 9% of 
which were eosinophils (1540 cells/mm3);
•	Erythrocyte	 sedimentation	 rate:	 120	 mm	 in	
the first hour;
•	Electrolytes,	urea,	creatinine,	bilirubin,	hepatic	
enzymes, lactate dehydrogenase (LDH): 
normal;
•	Blood	cultures,	urine	culture,	serologic	testing	
for HIV, parasitological tests: negative;
•	Initial	 chest	X-ray	 (Figure	1):	extensive	areas	
of consolidation throughout the left lung and 
with predominantly peripheral distribution in 
the right lung;
•	Initial	 computed	 tomography	 scan	 of	 the	
chest (Figure 2): diffuse areas of consolidation 
in the left lung (with volumetric loss and air 
Figure 1 - Initial	 chest	 X-ray.	 Extensive	 areas	 of	
consolidation, involving the entire left lung and presenting 
predominantly peripheral distribution in the right lung.
Figure 2 - Initial computed tomography of the chest. 
Diffuse areas of consolidation in the left lung, with 
deviation of the anterior junction line to the left 
(volumetric loss) and air bronchograms; peripheral 
consolidations, and areas of ground-glass attenuation in 
the right lung.
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together with elevated numbers of eosinophils in the 
blood, in the BAL, and in the pleural effusion. In the 
differential diagnoses of pulmonary eosinophilia, 
the following were considered not very probable: 
chronic eosinophilic pneumonia (based on the acute 
clinical presentation); Churg-Strauss syndrome 
(since there were no signs of peripheral neuropathy 
and no history of asthma); simple pulmonary eosi-
nophilia (due to the negative parasitological test 
results and the severe clinical presentation); allergic 
bronchopulmonary aspergillosis (given the lack of a 
history of asthma, bronchiectasis, or cystic fibrosis); 
and hypereosinophilic syndrome (based on the 
absence of extrapulmonary involvement).
There was a clear temporal relationship between 
the onset of the clinical symptoms and the use of 
several substances, making the hypothesis of drug-
induced pulmonary eosinophilia more likely. Among 
the substances used, L-tryptophan and hydrox-
ytryptophan might be associated with pulmonary 
infiltrate and eosinophilia.(1,8) Fluoxetine might be 
associated with subacute interstitial pneumonia, 
although there have been no reports of pulmonary 
eosinophilia.(9)
By the time EMS was described, the diagnostic 
criteria included incapacitating myalgia, periph-
eral eosinophilia > 1000 cells/mm3, and absence 
of infection or neoplasia that would explain the 
clinical symptoms.(2,8,10-12) Although L-tryptophan 
intake was not a diagnostic criterion, 86 to 97% 
of the patients reported it, with doses ranging from 
500 to 12,000 mg/day, and a four-week to six-year 
interval between the initial intake and the onset of 
the clinical symptoms.(2-4) The association described 
suggests a causal relationship between the drug 
intake and EMS, although such a relationship could 
not be confirmed.(6,7,13) Other authors believe that 
the accumulation of L-tryptophan metabolites is 
responsible for such clinical manifestations.(1)
The numerous cases of EMS described have 
widened the range of clinical signs and symptoms, 
allowing us to state that the disease is characterized 
by an acute phase, with an approximate duration of 
four months, in which there might be incapacitating 
myalgia, fever, weight loss, weakness, dyspnea, 
cough, chest pain, peripheral edema, arthralgia, 
exanthema, paresthesia, hyperesthesia, cutaneous 
thickening, pruritus, dyspepsia, and palpitations, 
as well as other symptoms.(2,8,11,14) In the chronic 
therapy (ceftriaxone and levofloxacin) and oxygen 
therapy. After one week, she still presented fever, 
hypoxemia, and dyspnea upon minimal exer-
tion, without radiological improvement. There 
was an increase in eosinophilia in the blood 
(2670 cells/mm3, 16%), which, in conjunction with 
the pleural eosinophilia and eosinophilia in the BAL, 
motivated the treatment with 125 mg of methyl-
prednisolone every 6 hours.
The evolution after the introduction of corti-
costeroid treatment was excellent: there was 
resolution of the fever and the eosinophilia within 
three days; after one week, there was improvement 
of the hypoxemia (SpO2 = 94% on room air) and 
of the radiological profile, with only a cystic image 
remaining in the left lung which was no longer 
detected	 in	 subsequent	 X-rays,	 being	 therefore	
interpreted as pneumatocele (Figure 3).
After 15 days, the patient presented no complaints 
and maintained SpO2 = 96% on room air. She was 
discharged with a prescription for oral prednisone 
(60 mg), gradually reduced until its discontinuation 
after four months. At the time of this writing, the 
patient presented fatigue of the proximal muscles 
of the lower limbs, with no respiratory complaints.
Discussion
The patient presented acute respiratory failure 
accompanied by bilateral pulmonary consolidations, 
Figure 3 - Chest	 X-ray	 after	 one	 week	 treatment,	 no	
longer showing the areas of consolidation or the linear, 
heterogeneous opacities in the right lung base. Although 
the cystic image (pneumatocele) is still visible in the left 
hemithorax, it was not observed on subsequent chest 
X-rays.
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treatment imperative, and the rapid response to the 
treatment made the biopsy unnecessary.
The treatment for EMS consists of drug discon-
tinuation and administration of corticosteroids: 5 
to 60 mg of oral prednisone a day for four weeks, 
with subsequent gradual reduction of the dose. 
Approximately 80% of patients present symptom 
improvement, the majority within the first three 
days of treatment, as was observed in this patient. 
The most refractory symptoms are fatigue and 
neurological (cognitive) symptoms. The estimated 
mortality is 2 to 6%, and the majority of deaths are 
due to ascending polyneuropathy with respiratory 
failure.(1)
Based on the clinical profile of acute respiratory 
failure accompanied by peripheral and pulmonary 
eosinophilia, in a context in which other eosinophilic 
diseases would be less probable, it is possible to 
suspect a causal relationship between the acute 
disease presented and L-tryptophan intake.
L-tryptophan is a substance widely used in Brazil. 
It is used indiscriminately, and without medical 
prescription control, since it is part of several 
‘formulas’ used in so-called ‘alternative’ treatments, 
as nutritional supplements, or in ‘ orthomolecular 
medicine’. Therefore, it is important that we be 
attentive to the possibility of the appearance of this 
broad spectrum of clinical manifestations, which, at 
an extreme level of severity, might evolve to acute 
respiratory failure and death.
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